Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks:a cross-sectional study by Andersen, Martin et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Synovial explant inflammatory mediator production corresponds to rheumatoid
arthritis imaging hallmarks
Andersen, Martin; Boesen, Mikael; Ellegaard, Karen; Christensen, Robin; Söderström, Kalle;
Søe, Niels; Spee, Pieter; Mørch, Ulrik Gw; Torp-Pedersen, Søren; Bartels, Else Marie;
Danneskiold-Samsøe, Bente; Vendel, Nina; Karlsson, Lars; Bliddal, Henning
Published in:
Arthritis Research & Therapy (Print)
DOI:
10.1186/ar4557
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Andersen, M., Boesen, M., Ellegaard, K., Christensen, R., Söderström, K., Søe, N., ... Bliddal, H. (2014).
Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks: a
cross-sectional study. Arthritis Research & Therapy (Print), 16(3), [R107]. https://doi.org/10.1186/ar4557
Download date: 03. Feb. 2020
Andersen et al. Arthritis Research & Therapy 2014, 16:R107
http://arthritis-research.com/content/16/3/R107RESEARCH ARTICLE Open AccessSynovial explant inflammatory mediator
production corresponds to rheumatoid arthritis
imaging hallmarks: a cross-sectional study
Martin Andersen1,2, Mikael Boesen3, Karen Ellegaard1, Robin Christensen1, Kalle Söderström2, Niels Søe4,
Pieter Spee2, Ulrik GW Mørch5, Søren Torp-Pedersen1, Else Marie Bartels1, Bente Danneskiold-Samsøe1,
Nina Vendel6, Lars Karlsson2 and Henning Bliddal1*Abstract
Introduction: Despite the widespread use of magnetic resonance imaging (MRI) and Doppler ultrasound for the
detection of rheumatoid arthritis (RA) disease activity, little is known regarding the association of imaging-detected
activity and synovial pathology. The purpose of this study was to compare site-specific release of inflammatory
mediators and evaluate the corresponding anatomical sites by examining colour Doppler ultrasound (CDUS) and
MRI scans.
Methods: RA patients were evaluated on the basis of CDUS and 3-T MRI scans and subsequently underwent
synovectomy using a needle arthroscopic procedure of the hand joints. The synovial tissue specimens were
incubated for 72 hours, and spontaneous release of monocyte chemoattractant protein 1 (MCP-1), interleukin
6 (IL-6), macrophage inflammatory protein 1β (MIP-1β) and IL-8 was measured by performing multiplex
immunoassays. Bone marrow oedema (BME), synovitis and erosion scores were estimated on the basis of the
rheumatoid arthritis magnetic resonance imaging score (RAMRIS). Mixed models were used for the statistical
analyses. Parsimony was achieved by omitting covariates with P > 0.1 from the statistical model.
Results: Tissue samples from 58 synovial sites were obtained from 25 patients. MCP-1 was associated with CDUS
activity (P = 0.009, approximate Spearman’s ρ = 0.41), RAMRIS BME score (P = 0.01, approximate Spearman’s
ρ = 0.42) and RAMRIS erosion score (P = 0.03, approximate Spearman’s ρ = 0.31). IL-6 was associated with RAMRIS
synovitis score (P = 0.04, approximate Spearman’s ρ = 0.50), BME score (P = 0.04, approximate Spearman’s ρ = 0.31)
and RAMRIS erosion score (P = 0.03, approximate Spearman’s ρ = 0.35). MIP-1β was associated with CDUS
activity (P = 0.02, approximate Spearman’s ρ = 0.38) and RAMRIS synovitis scores (P = 0.02, approximate
Spearman’s ρ = 0.63). IL-8 associations with imaging outcome measures did not reach statistical significance.
Conclusions: The association between imaging activity and synovial inflammatory mediators underscores the
high sensitivity of CDUS and MRI in the evaluation of RA disease activity. The associations found in our present
study have different implications for synovial mediator releases and corresponding imaging signs. For example,
MCP-1 and IL-6 were associated with both general inflammation and bone destruction, in contrast to MIP-1β,
which was involved solely in general synovitis. The lack of association of IL-8 with synovitis was likely underestimated
because of a large proportion of samples above assay detection limits among the patients with the highest
synovitis scores.* Correspondence: henning.bliddal@regionh.dk
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterised by progressive joint damage. The aeti-
ology of RA is, to a large extent, unknown, and current
therapies are aimed at reducing the inflammatory disease
burden. Recent data support the practice of frequent mon-
itoring of disease activity in RA patients to achieve remis-
sion faster [1,2]. However, patients may still experience
radiographic progression of bone erosions, despite being
judged to be in clinical remission [1,3,4]. The emergence
of imaging techniques such as ultrasound (US) and mag-
netic resonance imaging (MRI) have paved the way for
detailed descriptions of joint inflammation and erosion.
These imaging modalities have recently been accepted as
part of the diagnostic criteria in RA [1,5]. Because inflam-
matory activity detected by MRI or Doppler ultrasound
(DUS) has shown to be a good predictor of disease course
and response to treatment, the expansion of the use of
these detection modalities in clinical assessments of RA
has been suggested [6-8].
The invasive front of the synovium—the pannus—is be-
lieved to be the main driver of cartilage degradation and
bone erosion; however, to the best of our knowledge, no re-
searchers to date have investigated the association of histo-
logical features of synovitis with the extent of bone marrow
oedema (BME) and erosions visualised by MRI. This infor-
mation would be interesting because the presence of clus-
ter of differentiation–positive (CD68+) macrophages in RA
synovium has been linked to the development of erosions
detected on radiographs [9]. Investigators who conducted
MRI-based studies focused mainly on, and demonstrated,
associations of MRI-detected synovitis and synovial histo-
pathology [10-12] with MRI-detected BME and osseous
histopathology [13-15]. Furthermore, previously published
data have generally been based on small sample sizes. Also,
the synovial material examined in the vast majority of cases
was obtained from knee joints of patients undergoing knee
joint replacement surgery in cases where inflammation due
to concomitant osteoarthritis may have confounded the re-
sults. Current evidence is based mainly on studies in which
the investigators assessed pathology on the basis of
whole-joint imaging, which may have decreased sensi-
tivity for the detection of local activity in the different
areas of the synovium.
Studies of RA synovial explants have demonstrated the
value of the capacity they provide for evaluating inflam-
matory output and the response to anti-inflammatory
treatment, as well as for visualising the morphologic fea-
tures of the RA synovium [16-24]. Several methods of
establishing synovial cultures have been described, but
the use of assays based on whole synovial tissue has
been recommended in order to maintain synovial archi-
tecture and cell-to-cell contact [25]. Researchers in prior
biopsy-based explant studies might not have taken theheterogeneous synovial tissue distribution into account,
however, thus compromising the explant assays’ ability to
detect overall joint inflammation [18,26]. In recent years,
novel immunoassay techniques, such as multiplex tech-
nology, have paved the way for simultaneous analysis
of multiple cytokines and chemokines in a small sample.
However, it has been shown that synovial production of
heterophilic antibodies (HAs), such as rheumatoid factor
(RF), can have a great impact on assay reliability if they are
not blocked [27]. In contrast to synovial biopsies, explants
consist of live cells, and the production of inflammatory
mediators from these intact tissue cultures may thus pro-
vide novel information about RA pathogenesis.
Our aim in this study was to compare the association
of synovial inflammatory mediator production with the
colour Doppler ultrasound (CDUS) fraction [28] and/or
the rheumatoid arthritis magnetic resonance imaging score
(RAMRIS) [7] using 3-T MRI scans of the corresponding
anatomical sites in the target hand. Obtaining synovial tis-
sue by synovectomy under direct visual control enabled us
to harvest as much of the synovium as possible from the
different anatomical sites of the hand joints. The results of
this study should thus provide novel insights into the asso-
ciation between synovial inflammatory mediators and RA
hallmarks.
Methods
Patients
Patients with RA [29] and synovial hypertrophy diagnosed
on the basis of greyscale US image analysis were eligible
for the study. We excluded patients who were under 18
years of age, allergic to local anaesthetics, undergoing anti-
coagulant treatment or taking a prednisolone dose above
10 mg/day, receiving intraarticular prednisolone injections
into the hand, had synovectomy performed within the pre-
vious 3 months or had bad skin at the site of interest.
Otherwise, no patient selection method was utilised. The
enrolment period dated from June 2011 through January
2013. Patient recruitment and clinical and imaging exami-
nations were performed at the outpatient clinic of the
Department of Rheumatology at Copenhagen University
Hospital, Bispebjerg and Frederiksberg, in Denmark. The
study was approved by the local ethics committee of the
capital region of Denmark (H-4-2009-117). The approval
covered all centres involved in the study, and signed,
informed consent was obtained from each patient. Further
details about the centres involved are given in the
Acknowledgements.
Imaging modalities
Ultrasound examination
The evaluation was performed by an experienced US
specialist (KE or STP) [31], and CDUS was used to as-
sess the vascularisation of the synovial tissue. The region
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maximal systolic colour fraction (CFmax) in the ROI was
selected as a marker of synovial inflammation. Colour
Doppler mode was chosen as a marker of synovial in-
flammation because the sensitivity of detecting synovial
blood flow achieved with the LOGIQ E9 imaging system
(GE Healthcare, Waukesha, WI, USA) was higher than
that possible using the power Doppler modality [32]. US
examinations were performed as previously described
using a 15-MHz center frequency linear array matrix
[31]. In brief, the Doppler preset was adjusted for max-
imum sensitivity at low flow (pulse repetition frequency
of 0.4 kHz, lowest wall filter of 45 Hz and 7.5-MHz
Doppler frequency), with Doppler gain just below noise
level. This preset remained unchanged throughout the
study period. In all patients, the wrists, proximal inter-
phalangeal (PIP) and metacarpophalangeal (MCP) joints
were examined by US to identify the joints with the
most pronounced involvement. All examinations were
performed from standardised dorsal and dorsolateral po-
sitions using specific anatomic landmarks in the US
image in the various positions [33]. Following identifica-
tion of the anatomic landmarks in the greyscale image,
the Doppler was activated and, while keeping the land-
marks in the image, the transducer was adjusted until
the scan plane with the most Doppler activity was iden-
tified. The transducer was held in this position for a
couple of heart cycles, whereupon the image was frozen.
By using the cineloop function, the frames with max-
imum and minimum Doppler activity corresponding to
the systole were stored and transferred to a processing
program. The synovial Doppler activity was calculated as
the ratio of the systolic CDUS pixel count per unit of
greyscale pixel count, defined as CFmax [28]. In the wrist,
the synovial tissues in the radiocarpal (RC) and midcar-
pal (MC) joints were evaluated separately if possible.
Colour Doppler mode images were chosen to detect
markers of synovial inflammation, because its sensitivity
in detecting synovial blood flow on the LOGIQ E9 im-
aging system was higher than that of the power Doppler
mode [32].
Ventral scanning positions were omitted because only
the dorsal part of the joint was synovectomised. The
examiner was blinded to all patient characteristics. A
table describing the anatomical landmarks is provided in
Additional file 1.
A table with definitions of the anatomical landmarks is
provided in Additional file 1.
Magnetic resonance imaging
MRI scans were evaluated by an experienced radiologist
(MB). All patients were examined while in a 3-T MRI scan-
ner (MAGNETOM Verio; Siemens, Erlangen, Germany)
using a 16-channel cardiac coil covering the target hand.Patients were supine with their hands alongside the
body as previously described [34]. Briefly, pre- and post-
contrast-enhanced T1-weighted coronal and axial short
tau inverted recovery (STIR) sequences were used to cal-
culate synovitis, BME and erosion RAMRIS scores. The
RAMRIS synovitis scores, which range from 0 to 3, cor-
respond to no, low, moderate and severe synovitis, re-
spectively, based on subjective evaluation. We used the
RAMRIS BME component to evaluate the extent of BME
from 0 to 3, where each step corresponded to a 33% in-
crease in BME. The RAMRIS erosion score ranged from 0
to 10, with each step corresponding to 10% increments in
bone area eroded in the anatomy of interest. The synovitis
scores were performed at the RC and MC levels in the
wrist. MRI-based scores for BME and erosion were aver-
aged according to the anatomic location of the synovect-
omy or if synovectomy positions had been pooled. MB
was blinded to all patient characteristics and US data.
Procedures
The needle arthroscopic procedures were carried out at
Section of Hand Surgery, Department of Orthopedics, at
Gentofte Hospital in Hellerup, Denmark. The synovial
explant culture assay was conducted at the Section of
Translational Immunology in the Biopharmaceutical Re-
search Unit at Novo Nordisk, Måløv, Denmark. Needle
arthroscopy was performed within 24 hours after clin-
ical, US and MRI examinations. The joints (up to two
per patient) that seemed most inflamed clinically and on
CDUS were referred for synovectomy [30]. Portals were
established laterally for access to the extensor tendons.
The RC part of the wrist joint was found at the level of
the scapholunate ligament. The radial, central and ulnar
joints were located during synovectomies between the
scaphoid bone and the distal radius, lunate bone and
distal radius, as well as between the triquetral bone and
the ulnar meniscus. The MC part of the wrist joint was
detected by using a needle probe 1 cm distal from the
transverse line of the RC part of the joint. Synovial tissue
was obtained from three compartments (between the
scaphoid and trapezoid, capitate and lunate, and triquet-
ral and hamate bones, respectively). For the PIP and
MCP joints, the landmarks for the portals were the small
concavities in the dorsoulnar and dorsoradial directions
for the central slip in the PIP joint and through the sa-
gittal band in the MCP joint. With these portal loca-
tions, it was possible to obtain good joint visualisation
and sufficient distance between the arthroscope, shaver
and joint structures. To match imaging pathology with
arthroscopic sampling of the synovium, the surgeon
(NS) was not blinded to the patient’s diagnosis, medica-
tion or US findings. The US description with localisation
of Doppler activity and anatomic landmarks enabled the
surgeon to sample synovium from the corresponding
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synovial samples by use of the local RAMRIS score com-
ponent corresponding to the synovectomised area.
Synovial explant cultures
The synovectomy product was transferred under sterile
conditions into 15-ml tubes containing RPMI 1640 and
GlutaMAX media (Gibco/Life Technologies, Grand Island,
NY, USA), 10% foetal bovine serum, 2% heat-inactivated
human serum, 1% penicillin and streptomycin (complete
medium (CM)). The synovium-containing tubes were kept
on wet ice until the explant culture was established and in-
cubated less than 90 minutes postsurgery. The synovial tis-
sue was centrifuged (4°C) at 1,400 rpm for 7 minutes. The
CM supernatant was removed by suction, and synovial
wet weight was determined. Synovial tissue was distributed
in multiple wells at 2 mg/200 μl of CM in a 96-well Nunc
MicroWell plate with Nunclon Delta Surface (Thermo
Fisher, Waltham, MA, USA) containing bovine bone slices
(IDS DT1BON1000-96; Immunodiagnostic Systems Ltd.
Boldon, UK). The synovial explant culture was placed in a
sterile incubator at 37°C, 100% humidity and 5% CO2 for
72 hours, after which supernatants were collected and
stored at <80°C until analysed.
Screening of synovial biomarkers of inflammation and
testing for HA interference were performed on explant su-
pernatants from eight study participants. The supernatants
were assessed by utilising the Human InflammationMAP
multiplex immunoassay (Myriad RBM, Austin, TX, USA),
which consists of a combination of three multiplex panels
to evaluate a total of 46 mediators. Because of budget limi-
tations, one of the three multiplex panels was selected for
the study. That panel consisted of 15 mediators, of which
interleukin 6 (IL-6), IL-8, monocyte chemoattractant pro-
tein 1 (MCP-1) and macrophage inflammatory protein 1β
(MIP-1β) could be measured reproducibly from the ex-
plant cultures. Subsequent experiments were focused on
these analytes. A complete list of the mediators tested is
given in Additional file 2. The significance of HA inter-
ference was tested prior to analysis by adding 200 μg/ml
HeteroBlock (Omega Biologicals, Bozeman, MT, USA),
which previously has been reported to block HA interfer-
ence [27]. For further validation of abolishment of possible
HA interference, supernatants were diluted in six serial di-
lutions from a twofold to sixty-four-fold dilution. Linearity
was preserved for all cytokines upon dilution (R2 = 0.99;
data not shown). Supernatant measurements were car-
ried out at the laboratories of Myriad RBM using the
Luminex multiplex platform (R&D Systems, Minneapolis,
MN, USA). Samples were transported in dry ice under
continuous temperature measurements and access to dry-
ice supplements. The average explant mediator production
explant culture was used in the statistical analysis. Super-
natants were added to 200 μg/ml HeteroBlock and run ata 100-fold dilution (stored at 2-fold dilution and further
diluted 50-fold when analysed). The lowest limit of de-
tection for the assay was defined by Myriad RBM as the
lowest concentration of an analyte in a sample at which
the coefficient of variation of replicate standard samples
was 30%. The lowest assay detection limits were 72 pg/ml
IL-6, 26 pg/ml IL-8, 240 pg/ml MCP-1 and 366 pg/ml
MIP-1β. Plate-to-plate variation was less than 10%. MA
had access to all patient data. However, none of the im-
aging data outcome measures were available at the time
the explant cultures were established.
Statistical analysis
Data were clustered within patients; thus a linear mixed
model was applied for the statistical tests in order to pre-
vent double-counting errors with inflated standard errors.
As previously described, parsimony in the statistical models
was achieved by omitting design variables and covariates
from the model if no statistical significance was determined
(P > 0.1). For model optimisation purposes, square root
and logarithmic transformations were applied to achieve
an approximate Gaussian distribution of residuals. The
Spearman’s ρ estimate was considered important to the
overall visual data interpretation. Because of double-
counting, these Spearman estimates are referred to as
approximate Spearman coefficients [35]. Statistical ana-
lyses were calculated using SAS version 9.2 software
(SAS Institute, Cary, NC, USA). MA and RC had access
to all data.
Results
Patient and sample characteristics
As Figure 1 shows, 25 patients were enrolled into the
study, 12 of whom were recruited from a previous study
[35]. Three patients who were offered participation de-
clined, and an additional three patients were excluded on
the basis of the US examination because of lack of synovial
hypertrophy in the hand joints (Figure 1). From among the
recruited patients, five (20%) were referred for synovect-
omy and the remaining twenty (80%) accepted our invita-
tion to participate in the study. The patient population
consisted primarily of RF and anticitrullinated peptide anti-
body (ACPA)–positive women with long-standing disease
and mean Disease Activity Score in 28 joints/C-reactive
protein (DAS-28-CRP) levels in the upper end of the mod-
erate disease activity interval. The majority (52%) of pa-
tients had high disease activity, and 36% had moderate
disease activity. Three patients had either low disease activ-
ity (n = 1) or were classified as in disease remission (n = 2)
on the basis of DAS28 criteria. Nearly one-third (n = 8)
were being treated with biological agents (abatacept (n = 1),
etanercept (n = 2), infliximab (n = 4) and rituximab (n = 1)).
Most other patients were being treated with metho-
trexate as monotherapy or in combination with other
Figure 1 Schematic of patient flow through the study, imaging procedures carried out, number of joints synovectomised and number
of established synovial cultures with corresponding imaging modalities used. MCP, Metacarpal phalangeal joint; MRI, Magnetic resonance
imaging; N, Total number of patients; n, Number of synovial explant samples; PIP, Proximal interphalangeal joint; US, Ultrasound.
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in each category) (Table 1).
Synovial explant mediator production and imaging
activity
Synovial explants
A total of 71 synovectomy specimens were received from
26 joints (17 wrist joints, 6 MCP joints and 3 PIP joints).
From among the 71 synovectomies, 58 synovial explant
cultures were established. On average, 22 wells were cul-
tured per synovectomy position (SD = 9.4). Three of the
joint positions received were used for other purposes, and
the remaining ten, due to sparse material, were pooled
with one or more joint positions from the same joint.
Synovectomy material was pooled from two cases, from
two MCP joints in one case and from two PIP joints in
the other case. In the cases where synovectomy material
was pooled, an average of the imaging data from thecorresponding positions was calculated. Three patients
had two joints included (that is, two synovectomies), but
only one patient with two joints synovectomised had cor-
responding imaging from both joints (MCP joints).
Magnetic resonance imaging
Nineteen (forty-two synovectomy positions) of twenty-five
patients underwent MRI. As presented in Table 2, the mean
RAMRIS BME component score was 2.05 (SD ±0.96),
which corresponds to a moderate degree of osteitis ranging
from one-third to two-thirds of the bone area. Three
patients (seven synovectomies) had no BME. Synovial
mediator levels among these patients were above detection
limits for MCP-1 (6 (85%) of 7 patients), IL-6 (4 (57%) of
7 patients), IL-8 (7 (100 %) of 7 patients) and MIP-1β
(1 (14%) of 7 patients). Among the 16 patients (35 syno-
vectomies) with BME >0, levels of the four measured cyto-
kines were above the assay’s lowest detection limit in 35
Table 1 Patient demographics and clinical characteristicsa
Variables Observations (N = 25)
Females, n (%) 19 (76%)
Mean age ± SD, yr (IQR) 56.2 ± 14.9 (26 to 77)
Disease duration, yr 12.3 [4.0 to 14.1] (0.9; 42.7)
RF-positive, n (%) 21 (84%)
Anti-CCP-positive, n (%) 22 (88%)
Mean DAS-28-CRP score (0 to 10) 4.8 ± 1.3 [2.2 to 6.8]
CRP, mg/L 20.9 [4 to 30] (1; 117)
VAS global (scale 0 to 100) 62.5 [41 to 83]
Tender joint count, 28 joints 7.1 [4 to 9] (0; 25)
Swollen joint count, 28 joints 7.8 [4 to 9] (1; 21)
DMARD monotherapy
MTX, n (%) 2 (8%)
SZS, n (%) 3 (12%)
LFU, n (%) 2 (8%)
DMARD combination treatment
MTX + SZS, n (%) 4 (16%)
MTX + SZS + HCQ, n (%) 3 (12%)
Biologic DMARDs (%) 8 (32%)
Prednisolone monotherapy, 5 mg/day 2 (8%)
No DMARDs (%) 1 (4%)
aCCP, Cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease
Activity Score in 28 joints; HCQ, Hydroxychloroquine; LFU, Leflunomide; MCP,
Metacarpophalangeal joint; MTX, Methotrexate; PIP, Proximal interphalangeal
joint; RF, Rheumatoid factor; SD, Standard deviation; SZS, Sulphasalazine; VAS,
Visual Analogue Scale. Values are median [Q1 to Q3], (min; max) or mean ± SD
unless otherwise stated.
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respectively.
Ultrasound
All 25 patients underwent CDUS. However, the synovec-
tomised joint was not scanned in one patient because of a
logistic accident; thus, 24 patients (56 synovectomy posi-
tions) were included for the statistical analysis. CDUS
scans showed moderate activity on average, with a CFmax
of 12%. However, 12 patients (48%; 7 with matching CDUS
and explant setup) had at least one US position with ab-
sence of Doppler activity. Among the 11 synovectomies
(11 (20%) of 55) cultured from these Doppler-negative po-
sitions, cytokine levels above the lowest detection limit
were 9 (81%) of 11 for MCP-1, 4 (64%) of 11 for IL-6, 10
(91%) of 11 for IL-8 and 5 (46%) of 11 for MIP-1β.
Associations between imaging activity and synovial
explant mediator production
The statistical models show an association between levels
of synovial IL-6 (P = 0.04, approximated Spearman’s ρ =0.50) and MIP-1β (P = 0.02, approximated Spearman’s ρ =
0.63) and the RAMRIS synovitis score in both the reduced
and full statistical models. IL-8 had statistically significant
associations in all model reduction steps apart from the
final step (P = 0.08, approximated Spearman’s ρ = 0.58),
whereas MCP-1 did not have a statistically significant asso-
ciation (P = 0.17, approximated Spearman’s ρ = 0.48) with
regard to the RAMRIS synovitis component score. Syn-
ovial perfusion, measured as CFmax, was associated with
levels of MCP-1 (P = 0.009, approximated Spearman’s ρ =
0.41) and MIP-1β (P = 0.02, approximated Spearman’s ρ =
0.38). In contrast, IL-6 (P = 0.34, approximated Spearman’s
ρ = 0.22) and IL-8 (P = 0.09, approximated Spearman’s ρ =
0.27) were not statistically significantly associated with syn-
ovial perfusion. Figure 2 shows scatterplots for the statisti-
cally significant associations between RAMRIS synovitis
score, CFmax and corresponding mediator release. Scatter-
plots illustrating imaging and explant mediator data not
meeting the criteria for statistical significance are provided
in Additional files 3 and 4.
Synovial MCP-1 (P = 0.01, approximated Spearman’s
ρ = 0.42) and IL-6 production (P = 0.04, approximated
Spearman’s ρ = 0.25) were associated with the RAMRIS
BME component score and the RAMRIS erosion compo-
nent score (P = 0.03, approximated Spearman’s ρ = 0.31
for MCP-1) and (P = 0.03, approximated Spearman’s
ρ = 0.35 for IL-6).
Table 3 provides a general overview of the findings,
including the remaining statistically insignificant find-
ings. Figure 3 shows scatterplots of the data distribu-
tions regarding RAMRIS BME and erosion scores and
synovial explant release. Additional files 5, 6, 7 and 8
provide details of the statistical model calculations, in-
cluding the stepwise covariate elimination. All media-
tors that were statistically significantly associated with
CFmax, RAMRIS synovitis score and RAMRIS BME
score were statistically significant in both the unadjusted
and adjusted models. With regard to the RAMRIS ero-
sion score, MCP-1 and IL-6 were above the statistical
significance level in the unadjusted model (P = 0.07 and
P = 0.08, respectively).
Table 3 presents the statistical associations between
RA explant mediator release after 72 hours of culture
and imaging activity. Imaging consisted of CDUS activ-
ity, reflected as the CFmax in the systole. MRI-based
activity outcomes were the RAMRIS components. A
mixed model was used for the statistical analysis (P <
0.05 was considered significant). In the reduced model,
covariates were excluded when the P-value was >0.10.
Table 3 contains the data from the reduced models. The
full models, including stepwise covariate elimination
steps and model optimisation transformation, are
provided in the Additional files. The prespecified
covariates included in the statistical model were joints
Table 2 Overview of imaging observations and explant activitya
Variable Observations No. patients(No. synovectomies) Median [IQR] (min;max)
Imaging
Focal RAMRIS BME score, 0-3
Wrist 12 (34) 1.8 [0.8 to 3.0] (0.0; 3.0)
MCP 4 (4) 2.0 [1.3 to 2.8] (0.0; 3.0)
PIP 3 (4) 2.0 [1.0 to 2.5] (1.0; 2.5)
Total 19 (42) 1.5 [1.0 to 2.8] (0.0; 3.0)
CFmax, 0-1
Wrist 17 (48) 0.08 [0.02 to 0.23] (0.0; 0.86)
MCP 4(4) 0.12 [0.05 to 0.34] (0.03; 0.52)
PIP 3(4) 0.06 [0.03 to 0.07](0.0: 0.08)
Total 24 (56) 0.08 [0.01 to 0.21] (0.0; 0.86)
Explant mediator production, pg/mL
MCP-1
Wrist 17 (48) 4,848 [1,138 to 15,000] (240.5; 46,450)
MCP 6 (6) 2,444 [840 to 11,175] (240.5; 31,336)
PIP 3 (4) 2,082 [986 to 2,707] (348; 3,053)
Total 25 (58) 3,865 [1,138 to 12,915] (240.5; 46,450)
IL-6
Wrist 17 (48) 8,465 [1,321 to 39469] (72.5; 266,857)
MCP 6 (6) 4,969 [391 to 37,496] (72.5; 534,340)
PIP 3 (4) 11,901 [1,761 to 29,205] (732; 37,400)
Total 25 (58) 8,031 [1,156 to 37,400] (72.5; 534,340)
IL-8
Wrist 17 (48) 21,129 [5,649 to 96,401] (26,5; 137,001)
MCP 6 (6) 21,132 [5,405 to 48,883] (4,571; 137,001)
PIP 3 (4) 20,730 [6,388 to 50,750] (2,017; 70,800)
Total 25 (58) 21,129 [5,503 to 89,643] (26.5; 137,001)
MIP-1β
Wrist 17 (48) 1,812 [530 to 6,828] (366.5; 28,420)
MCP 6 (6) 1,078 [577 to 2,786] (366.5; 19,120)
PIP 3 (4) 555 [354 to 1,724] (366.5; 2,705)
Total 25 (58) 1,331 [502 to 5,196] (366.5; 28,420)
Depicting an overview of the imaging activity and synovial explant mediator production. Avr. = average, CFmax = colour fraction measured in the systole,
IL-6 = Interleukin 6, IL-8 = Interleukin 8, IQR = Interquartile range (3rd quartile – 1st quartile), Max. = maximum, MCP = Metacarpo-phalangeal joint,
MCP-1 = macrophage chemoattractant protein 1, Min. = minimum, MIP-1b = Macrophage inflammatory protein 1 beta, no. = number , PIP = Proximal
interphalangeal joint, RAMRIS BME Score = Rheumatoid Arthritis Magnetic Ressonance Bone Marrow Oedema Score.
1 Mean ± Standard deviation.
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ition (ulnar, central, radial or mixed for pooled syno-
vectomy positions) and side (left or right).
Associations between DAS-28-CRP scores and synovial
explant mediator production
Ancillary analyses using Spearman’s rank correlations
showed that IL-6 (r = 0.52, P = 0.008), IL-8 (r = 0.46,P = 0.026) and MCP-1 (r = 0.44, P = 0.029) were statisti-
cally significantly correlated to DAS-28-CRP score. The
correlation of MIP-1β to DAS-28-CRP score did not
reach statistical significance (r = 0.28, P = 0.169).
Discussion
In this study of the hand joints of RA patients, the degree
of synovitis—estimated by CDUS using the CFmax and by
Figure 2 Scatterplots depicting synovitis, defined as synovial perfusion by maximal systolic colour fraction and by magnetic resonance
imaging using the rheumatoid arthritis magnetic resonance imaging score for synovitis vs. synovial explant release after 72 hours in
culture. The statistically significant plots are shown. For the remaining plots, see Additional file 3. Rheumatoid arthritis magnetic resonance
imaging scores (RAMRIS) for synovitis are shown in (a) and (b). (a) Interleukin 6 (P = 0.04, approximate ρ = 0.50). (b) Macrophage inflammatory
protein 1β (P = 0.02, approximate ρ =0.63). Maximal systolic colour fraction (CFmax) values are shown in (c) and (d). (c) Monocyte
chemoattractant protein 1 (P = 0.009, approximate ρ = 0.41). (d) Macrophage inflammatory protein 1β (P = 0.02, approximate ρ = 0.38).
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synovial explant production of key inflammatory media-
tors. This finding supports previously published observa-
tions that DUS and MRI are sensitive imaging modalities
for the detection of local inflammation. Among the four
mediators investigated in our present study, we observed
an interesting polarisation. Whereas IL-6, MCP-1 andTable 3 Statistical associations with rheumatoid arthritis expl
Imaging/mediator CFmax RAMRIS synovitis
P-value (approximate ρ) P-value (approxi
MCP-1 0.009 (0.41) 0.17 (0.48)
IL-6 0.23 (0.22) 0.04 (0.50)
IL-8 0.09 (0.27) 0.08 (0.58)
MIP-1β 0.02 (0.38) 0.02 (0.63)
aCFmax, Maximal systolic colour fraction; BME, Bone marrow oedema; IL, Interleukin;
protein 1β; RAMRIS, Rheumatoid arthritis magnetic resonance imaging score.
A mixed model has been used for the statistical analysis: P < 0.05 was considered si
contains the data from the reduced models. The full models including stepwise cov
in the supplementary files.
The pre-specified covariates included in the statistical model: Joint Synovectomized
pooled synovectomy positions; Side = left or right;
Approx. rho = approximated Spearman’s rho; RAMRIS BME = RAMRIS bone marrow e
RAMRIS synovitis = RAMRIS synovitis score component; IL-6 = Interleukin 6; IL-8 = Int
Inflammatory Protein 1 beta.MIP-1β were associated with synovitis detected by MRI
or CFmax in combination, only MCP-1 and IL-6 were asso-
ciated with the extent of BME and bone erosions visua-
lised by MRI. Furthermore IL-6, IL-8 and MCP-1
production were correlated with DAS-28-CRP score, indi-
cating that the local synovial mediator production reflects
systemic disease.ant mediator release at 72 hours vs. at time of imaginga
RAMRIS BME RAMRIS erosion
mate ρ) P-value (approximate ρ) P-value (approximate ρ)
0.01 (0.42) 0.03 (0.31)
0.04 (0.25) 0.03 (0.35)
0.16 (0.27) 0.07 (0.43)
0.95 (0.35) 0.62 (0.30)
MCP-1, Monocyte chemoattractant protein 1; MIP-1, Macrophage inflammatory
gnificant. In the reduced model, covariates were excluded if P > 0.10. This table
ariate elimination steps and model optimization transformation can be found
=Wrist, MCP or PIP; Synovectomy position = Ulnar, central, radial, or mixed for
dema component; RAMRIS Erosion = RAMRIS erosion score component;
erleukin 8, MCP-1 = Monocyte chemoattractant protein 1; MIP-1b =Macrophage
Figure 3 Scatterplots depicting bone marrow oedema and bone erosion measured by the rheumatoid arthritis magnetic resonance
imaging score vs. synovial explant release after 72 hours in culture. The statistically significant plots are shown. For the remaining plots,
see Additional file 4. Bone marrow oedema (BME) rheumatoid arthritis magnetic resonance imaging scores (RAMRIS) are shown in (a) and (b).
(a) Monocyte chemoattractant protein 1 (P = 0.01, approximate ρ = 0.42). (B) Interleukin 6 (P = 0.04, approximate ρ = 0.25). Bone erosion
RAMRIS scores are shown in (c) and (d). (c) Monocyte chemoattractant protein 1 (P = 0.03, approximate ρ = 0.31). (d) Interleukin 6 (P = 0.03,
approximate ρ = 0.35).
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accord with results produced in biopsy studies in which
investigators examined differences in cellular populations
and mediator and chemokine receptor expression at the
cartilage–pannus junction (CPJ), which is believed to be
the site driving the erosive process in the bones of RA pa-
tients. In biopsies, IL-6 expression was found exclusively
at the CPJ, in contrast to IL-8-positive cells (primarily
CD68+ macrophages), the vast majority of which were
located at non-CPJ locations [36,37]. The picture is not
completely clear, however, because CD68+ macrophages
have been linked to radiographically visualised RA pro-
gression [38]. MCP-1 and its receptor, chemokine (C-C
motif) receptor 2, was located with the highest density
near the synovial lining, in contrast to MIP-1β, which had
the most pronounced staining in synovial endothelium.
MCP-1- and MIP-1β-positive cells, however, were located
throughout the synovium [39]. The lack of correlation
with DAS-28-CRP score and MIP-1β may indicate that
synovial MIP-1β production has a role in RA pathogenesis
that is more marginal than that of IL-8, which
also had a strong signal (approximate ρ = 0.58) to MRI-
detected synovitis. In contrast to MIP-1β, IL-8 was statisti-
cally significantly associated with DAS-28-CRP score.However, further studies are needed to verify the clinical
significance of the cytokine expression pattern in the
synovium.
The lack of association between BME and bone ero-
sion with synovial IL-8 and MIP-1β release can be ex-
plained by the main production of these mediators’
originating from non-CPJ areas in the synovium. Re-
searchers in two large clinical studies reported a lack of
association of radiographic outcome and synovitis in
anti–tumour necrosis factor α (anti-TNF-α)–treated co-
horts [40,41]. These findings support our observations of
different implications of these mediators in RA pathogen-
esis and suggest that changes in mediator profiles upon
treatment may be able to predict and stratify disease out-
comes with regard to synovitis and bone destruction.
Some limitations should be taken into account concern-
ing day-to-day variations in our study. The RA patients in
our study had DUS and MRI performed 24 hours prior to
surgery, and day-to-day variations may have affected the
reported associations [42]. Furthermore, the experimental
setup did not include synovectomies from healthy con-
trols. Therefore, baseline information on mediator release
from ‘normal’ synovium was not possible. However, cyto-
kine profiling of synovial fluid from healthy controls using
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Hercules, CA, USA) showed that the synovial fluid quan-
tities of the four mediators were extremely low, with
MCP-1 having the highest mean concentration at 0.5 ± 0.4
pg/ml [30]. We therefore believe that cytokine levels above
assay detection limits (lowest detection limit of IL-8 = 26
pg/ml) should reflect synovial pathology. Taking the very
low synovial fluid cytokine concentrations into account,
the relatively high cutoff values for the assay’s lowest de-
tection limits may have resulted in some overestimation of
synovial explant cytokine release. Considering the gener-
ally high concentration of synovial explant mediator re-
lease, an assay imprecision in the range of 26 to 360 pg/
ml, depending on the cytokine, should not affect the over-
all associations with regard to imaging.
The results of this study show a noteworthy variation
in synovial cytokine production and corresponding im-
aging pathology. The absence of signalling on DUS scans
does not rule out synovial cytokine production. These
findings are in accord with the results of our previous
study in which DUS-detected activity was compared to
synovial histopathology in a similar group of RA patients
[35]. That previous study did not include grading of the
synovial hypertrophy, because the images were obtained
only for evaluation of colour Doppler. Further research
on the association of synovial hypertrophy with synovial
inflammation may provide important insights into RA
disease pathogenesis.
Cellular stress inflicted by the in vitro circumstances
could perhaps have skewed the mediator release from
the explant cultures, resulting in higher mediator con-
centrations. This phenomenon did not generally occur,
however, as low concentrations of synovial mediators
were observed in some of the explants cultured from
sites with moderate to high RAMRIS scores and in the
presence of DUS-visualised activity. The observed varia-
tions may in fact have been caused by different kinetics
controlling synovial perfusion, cellularity and mediator
production. These factors may also account for the dif-
ferences in the cytokines associated with synovial perfu-
sion detected by CFmax and with synovitis detected by
MRI. Use of biological DMARDs (bDMARDs) may re-
sult in changes in cytokine production, but, because of
the limited population size in this study, it was not pos-
sible to adjust for the different treatment modalities.
Further research focused on explants and imaging in a
prospective study may clarify the robustness of this
method for prognostic use in bDMARD treatment. We
made a great effort in designing the study to guide the
area of the synovectomy on the basis of the US data;
however, a completely accurate match was not possible.
MRI mapping of the RAMRIS synovitis score was
performed at a regional level in the wrist (RC or MC).
Furthermore, BME and bone erosion data weredetermined as averaged values derived from the synovec-
tomised area. This may represent a source of bias be-
cause the synovium was removed only from the dorsal
part of the joint. Unfortunately, because of insufficient
matching imaging data, a comparison of MRI and CDUS
regarding their utility in detecting synovitis was not
possible.
The reason IL-8 did not reach a statistically significant
association with the MRI synovitis score is likely due to
the large number of wells (52%) above the assay’s upper
detection limit. None of the other cytokine levels were
above the assay detection limit. Among the wells that were
above detection levels, an MRI-based synovitis score of 3
was found in 72%, whereas the remaining wells had a score
of 2. Budget considerations and the high dilution factors
limited the possibilities of including several key inflamma-
tory mediator candidates for measurement, despite their
presence in supernatants. These candidate mediators in-
cluded TNF-α, vascular endothelial growth factor, matrix
metalloprotease 3, tissue inhibitor of metalloprotease 1,
IL-10 and interferon γ. The synovial explant model there-
fore offers significant information regarding synovial in-
flammatory activity. Interestingly, IL-1β levels were very
low and under the detection limit (0.57 pg/ml) in five of
eight patients in the initial screening. A recent publication
also described low levels of IL-1β and TNF-α based on a
whole-tissue synovial explant system [43]. This informa-
tion is in contrast to reports of studies in which enzyme-
digested synovial tissue was used, possibly due to changes
induced by the digestion process (for example, inhibition
of formation of three-dimensional cell layers or lipopoly-
saccharides in the collagenase, which are potent inducers
of IL-1β and TNF-α) [44].
All patients included in our present study had synovial
pathology defined by synovial hypertrophy visualised on
US scans. Several sites were without DUS-visualised ac-
tivity, and one case (three synovial explant positions)
was judged to have no synovitis on the basis of MRI.
Our findings emphasise the importance of considering
the degree of greyscale synovitis when evaluating RA pa-
tients on the basis of US in the clinic.Conclusion
In this study, we show that MRI and CDUS are highly
sensitive tools for the detection of synovial pathology.
Furthermore, synovial explants can identify imaging
biomarkers associated with the RA disease hallmarks
synovitis, BME and bone erosions, and the production
of several proinflammatory cytokines correlates with
overall disease activity, indicating great potential for
the use of synovial explant assays in the quest for the
identification of novel pathways to aid in understanding
RA pathology.
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Additional file 1: Table depicting the anatomic landmarks defining
each ultrasound scan position. Standardized ultrasound scanning
planes, image selection, and image quantification. Description of data:
overview of the standardized ultrasound scanning planes and description
of the colour Doppler quantification method.
Additional file 2: Table giving an overview of the multiplex panel
chosen for the supernatant analysis and description of the
multiplex panel and rationale behind the selection of synovial
mediators used in the study.
Additional file 3: Figure showing scatterplots of statistically
insignificant associations of synovial mediator release and CFmax and
RAMRIS synovitis score. Scatterplots depict synovitis, defined as synovial
perfusion by colour fraction max (CFmax) and the RAMRIS synovitis score vs.
synovial explant release (in pg/ml) after 72 hours of culture that did not reach
a statistically significant association. For CFmax: (a) IL-6 (P = 0.23, approximated
ρ = 0.22). (b) IL-8 (P = 0.09, approximated ρ = 0.27). For the RAMRIS synovitis
score: (c) MCP-1 (P = 0.17, approximated ρ = 0.48). (d) IL-8 (P = 0.05,
approximated ρ = 0.58). IL, Interleukin; MCP-1, Monocyte chemoattractant
protein 1; RAMRIS, Rheumatoid arthritis magnetic resonance imaging score.
Additional file 4: Figure showing scatterplots of statistically
insignificant associations of synovial mediator release and RAMRIS
BME and RAMRIS erosion scores. Scatterplots depict bone erosion
measured by the RAMRIS bone marrow oedema (BME) and bone erosion
score vs. synovial explant release (pg/ml) after 72 hours in culture that did
not reach statistical significance. RAMRIS BME: (a) IL-8 (P = 0.16, approximated
ρ = 0.27). (b) MIP-1β (P = 0.95, approximated ρ = 0.35). RAMRIS erosion:
(c) IL-8 (P = 0.07, approximated ρ = 0.43). (d) MIP-1β (P = 0.62, approximated
ρ = 0.30). IL, Interleukin; MIP-1β, Monocyte inflammatory protein 1β; RAMRIS,
Rheumatoid arthritis magnetic resonance imaging score.
Additional file 5: Table providing an overview of the stepwise
covariate elimination in the statistical models with regard to synovial
mediator production and CDUS activity. This table depicts the statistical
associations between colour Doppler ultrasound (p = CDUS) activity and
synovial explant mediator release after 72 hours in culture. A mixed model
has been used for the statistical analysis. P < 0.05 was considered significant.
In the reduced model, covariates were excluded if the P-value was >0.10.
All of the four prespecified covariates tested in the models are shown.
Additional file 6: Table giving an overview of the stepwise
covariate elimination in the statistical models with regard to
synovial mediator production and RAMRIS synovitis score. This table
depicts the statistical associations between the rheumatoid arthritis
magnetic resonance imaging synovitis score (RAMRIS) component in the
part of the joint that was synovectomised and synovial explant mediator
release after 72 hours in culture. A mixed model was used for the
statistical analysis. P < 0.05 was considered significant. In the reduced
model, covariates were excluded when P-values were >0.10. All of the
four prespecified covariates tested in the models are shown.
Additional file 7: Table providing an overview of the stepwise
covariate elimination in the statistical models with regard to
synovial mediator production and RAMRIS BME score. This table
depicts the statistical associations between the rheumatoid arthritis
magnetic resonance imaging bone marrow oedema score (focal RAMRIS
BME) component and synovial explant mediator release after 72 hours in
culture. A mixed model was used for the statistical analysis. P < 0.05 was
considered significant. In the reduced model, covariates were excluded if
P-values were >0.10. All of the four prespecified covariates tested in the
models are shown.
Additional file 8: Table depicting the statistical associations between
the rheumatoid arthritis magnetic resonance imaging erosion score
(RAMRIS) component in the part of the joint that was synovectomised
and synovial explant mediator release after 72 hours in culture.
Overview of the stepwise covariate elimination in the statistical models with
regards to synovial mediator production and the RAMRIS erosion score.
A mixed model was used for the statistical analysis. P < 0.05 was considered
significant. In the reduced model, covariates were excluded if P > 0.10. All of
the four prespecified covariates tested in the models are shown.Abbreviations
BME: Bone marrow oedema; CD68+: Cluster of differentiation 68–positive;
CDUS: Colour Doppler ultrasound; CFmax: Maximal systolic colour fraction;
CM: Complete medium; CPJ: Cartilage pannus junction; CRP: C-reactive
protein; HA: Heterophilic antibody; HCQ: Hydroxychloroquine; IL: Interleukin;
IQR: Interquartile range; LFU: Leflunomide; MC: Midcarpal; MCP: Metacarpal
phalangeal; MCP-1: Monocyte chemoattractant protein 1; MIP-
1β: Macrophage inflammatory protein 1β; MMP-3: Matrix metalloprotease 3;
MRI: Magnetic resonance imaging; MTX: Methotrexate; PIP: Proximal
interphalangeal; Q1: First quartile; Q3: Third quartile; RAMRIS: Rheumatoid
arthritis magnetic resonance imaging score; RC: Radiocarpal; ROI: Region of
interest; SD: Standard deviation; STIR: Short tau inverted recovery;
SZS: Sulphasalazine; TIMP-1: Tissue inhibitor of metalloprotease 1;
TNF-α: Tumour necrosis factor α; VAS: Visual Analogue Scale; VEGF:
Vascular endothelial growth factor.
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